Mantle cell lymphoma (MCL) is an aggressive and incurable malignant disease. Despite of general chemotherapy, relapse and mortality are common, highlighting the need for the development of novel targeted drugs or combination of therapeutic regimens. Recently, several drugs that target the B-cell receptor (BCR) signaling pathway, especially the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, have demonstrated notable therapeutic effects in relapsed/refractory patients, which indicate that pharmacological inhibition of BCR pathway holds promise in MCL treatment. Here, we have developed a novel irreversible BTK inhibitor, PLS-123, that has more potent and selective anti-tumor activity than ibrutinib in vitro and in vivo. Using in vitro screening, we discovered that the combination of PLS-123 and the mammalian target of rapamycin (mTOR) inhibitor everolimus exert synergistic activity in attenuating proliferation and motility of MCL cell lines. Simultaneous inhibition of BTK and mTOR resulted in marked induction of apoptosis and cell cycle arrest in the G1 phase, which were accompanied by upregulation of pro-apoptotic proteins (cleaved Caspase-3, cleaved PARP and Bax), repression of anti-apoptotic proteins (Mcl-1, Bcl-xl and XIAP), and downregulation of regulators of the G1/S phase transition (CDK2, CDK4, CDK6 and Cyclin D1). Gene expression profile analysis revealed simultaneous treatment with these agents led to inhibition of the JAK2/STAT3, AKT/mTOR signaling pathways and SGK1 expression. Finally, the anti-tumor and pro-apoptotic activities of combination strategy have also been demonstrated using xenograft mice models. Taken together, simultaneous suppression of BTK and mTOR may be indicated as a potential therapeutic modality for the treatment of MCL.
an aggressive clinical course with poor outcome and median survival of 5-7 years after diagnosis, 1 and a minority of patients is characterized by an indolent clinical course. 6 Although standard combination chemotherapy, intensive chemotherapy, and autologous hematopoietic stem-cell transplantation (AHSCT) have significantly improved initial response rates, 7 60-90% of MCL patients either relapse or continue to progress. 8 Given the lack of successful treatment options for this disease, new treatment strategies designed to target the molecular mechanisms underlying the development of MCL are urgently needed.
Bruton's tyrosine kinase (BTK) is a member of the Tec family of tyrosine kinases and is a key regulator of the B-cell receptor (BCR) signaling pathway. 9 This pathway plays a critical role in regulating B-cell survival, proliferation and maturation. BCR activity also regulates several downstream signaling pathways, including the mitogen-activated protein kinase (MAPK), protein kinase (PK)C, NF-jB and AKT pathways. Chronic activation of the BCR signaling pathway has been implicated in the pathogenesis of many subtypes of B-cell malignancies including MCL. 10 Recent evidence suggests that pharmacological inhibition of BCR signaling using the irreversible BTK inhibitor, ibrutinib, significantly increases tumor regression in relapsed or refractory MCL patients. A response rate of 68% has been observed, with a complete response rate of 21% and a partial response of 47%. 11 However, ibrutinib has some side effects, such as bleeding, diarrhea, nausea and fatigue. These side effects may be due, in part, to non-specific binding to kinases other than BTK, including Tec, epidermal growth factor receptor (EGFR), B-lymphocyte kinase and interleukin-2-inducible T-cell kinase (ITK). 12 Moreover, despite its high level of clinical activity, primary and acquired resistance to ibrutinib therapy is commonly observed. A cysteine-to-serine (C481S) mutation in BTK at the binding site of ibrutinib renders the drug-protein interaction reversible, resulting in only partial inhibition, as demonstrated by the enhanced BTK and AKT activities in ibrutinib resistant MCL patients. [13] [14] [15] In order to overcome the emerging resistance to and off-target side effect of ibrutinib, more selective second-generation BTK inhibitors have been explored. [15] [16] [17] Our developed novel BTK inhibitor PLS-123 had exhibited different selectivity profile and more potent antitumor activity than ibrutinib. Compared with ibrutinib, which only suppresses BTK phosphorylation at Tyr223, PLS-123 exhibits a dual mode of action by inhibiting the catalytic activity of BTK at Tyr551 and preventing self-activation of the protein at Tyr223. Importantly, PLS-123 exhibited greater potency than ibrutinib in 14 different B-NHL cell lines, patients' own primary tumor cells, and mouse xenograft models through precise regulation of BCR signaling and downstream cascades. 16 Gene expression profiling revealed that the PI3K/AKT/ mTOR pathway is upregulated in MCL cells, which plays important roles in promotion of tumor cell survival and proliferation. 18, 19 Everolimus, an orally administered inhibitor of the mTOR pathway, has been approved by the United States Food and Drug Administration (FDA) for treatment of renal cell carcinoma. 20 Recent clinical trials have demonstrated that it exhibits modest anti-tumor activities with overall response rates of 20-32% and is acceptably tolerated in patients with MCL. 21, 22 However, since the single agent has achieved only moderate efficacy, the development of combination therapies may represent a valuable approach in the treatment of this disease.
In this study, we analyzed the synergistic anti-tumor activity of everolimus and PLS-123 in MCL. Our results suggested that the combination treatment of the mTOR inhibitor everolimus and the second-generation BTK inhibitor PLS-123, promises to be an attractive therapeutic approach in patients diagnosed with MCL.
Material and Methods

Cell lines and culture conditions
The human MCL cell lines (Granta519, Z138, Mino, JVM2, Jeko-1) were obtained from Dr. Fu in University of Nebraska Medical Center in USA. These cells were grown in DMEM-LOW (Gibco, Life technology) supplemented with 10% fetal bovine serum (FBS; Gibco, Life technology), penicillin/streptomycin and glutamine in a humidified atmosphere of 5% CO 2 at 378C.
Reagents and antibodies
Everolimus (Cat No. S1120) and Rapamycin (Cat No. S1039) were purchased from Selleck Chemicals (Houston) and dissolved to a stock solution in dimethylsulfoxide (DMSO) in 2808C. The BTK inhibitor PLS-123 was synthesized at the laboratory of Pro. Zhengying Pan at Peking University ShenZhen Graduate School according to a previously published procedure. 23 Antibodies 
Quantification of apoptosis and cell cycle
Cells were harvested and washed once with phosphate buffer solution (PBS), then cells were resuspended with 13 Binding Buffer and labeled using Annexin-V-FITC and propidiumiodide (PI) according to the manufacturer's protocol of the Annexin-V-FITC apoptosis detection kit purchased from Dojindo Laboratories (Cat No. AD10, Kumamoto, Japan). The labeled cells were analyzed by BD Accuri C6 flow cytometer (BD, Biosciences, San Jose, CA).
Cells analyzed for cell cycle were collected and washed with PBS, then fixed using 75% ice-cold ethanol at 48C overnight. The fixed cells were centrifuged and washed with PBS, then suspended cells in PBS containing 100 lg/ml RNAase A (Cat No. GE101, Transgen Biotech, Beijing, China) for 30 min at 378C, then added PI staining buffer (Cat No. P4170, Sigma-Aldrich, St. Louis, MO) to final concentration of 50 lg/ml and incubated in the dark at room temperature for 30 min. The samples were analyzed using BD Accuri C6 flow cytometer.
Invasion and migration assay
The equal number of tumor cells was pretreated with PLS-123 or/and everolimus or vehicle for the indicated time. Then in the invasion assay, tumor cells were harvested and washed once with PBS, and plated in Matrigel basement membrane matrix-coated upper chambers in a trans-well plate with 8.0-lM pores (Cat NO. 354480, Corning Costar, Cambridge, MA). Cell migration was performed by transwell assay (Cat NO. 3422, Corning Costar, Cambridge, MA). The lower chambers were filled with DMEMLOW medium supplemented with 30% FBS, and the upper chambers were filled with serum-free DMEMLOW, then the cells were incubated for 24 hrs at 378C. The cells that migrated from the upper chamber were collected, and counted using Cell Titer-Glo Luminescent Cell viability assay system measured by LMax II mentioned above.
Microarray hybridization and gene expression analysis
Sample processing, microarray hybridization and gene expression analyses were performed using the Affymetrix GeneChip System (Bangfei Bioscience, Beijing, China). The biotinylated cRNA was fragmented and hybridized to the GeneChip Human Genome U133 Plus 2.0 microarrays (Affymetrix). Pathway analysis was used to identify the significant pathway of the differential genes according to KEGG database.
RNA extraction and real-time PCR
Total RNA was extracted using Trizol reagent (Cat No. 15596-026, Life Technologies, Carlsbad, CA), according to the manufacture's instructions. Reverse transcription was performed using TransScript First-Strand cDNA Synthesis SuperMix (Cat No. AT301, TransGen Biotech, Beijing, China). Real-Time PCR was performed with the specially designed primers and Go Taq qPCR Master Mix (Cat No. A6001, Promega Corporation, Madison). The primers were as follows: SGK1 sense AAGCAGAGGAGGATGGGTC, antisense GAACATTCCGCTCCGACA; GAPDH sense GCA-CCGTCAAGGCTGAGAAC, antisense TGGTGAAGACGC-CAGTGGA. The fold change in mRNA was calculated by the 2 -DDCt method.
Lentivirus-mediated small hairpin RNA (lenti-shRNA) against SGK1
The Lenti-shRNA vector system (pGCSIL-GFP) was constructed, packed, and purified by GeneChem Company (Shanghai, China), and was manipulated according to the protocol provided by the manufacturer. The negative control
Cancer Therapy and Prevention lentiviral vector containing non-silencing shRNA was used. The depletion efficiency was evaluated by western blot analysis.
In situ apoptosis detection by tunel staining
To detect DNA fragmentation and consequently apoptotic cells in tumor specimens, paraffin-embedded, 5 lM thick sections from Granta519 tumor samples were used to identified apoptotic cells by staining using In situ Cell Death Detection Kit (Cat No. 11684795910, Roche, Mannheim, Germany).
In vivo studies
Six-to eight-week-old female CB.17 severe combined immunodeficiency disease (SCID) mice were obtained from HFK Bioscience (Beijing, China). The mice were maintained in accordance with the Guide for the Care and Use of Laboratory Animals, which were approved by the Peking University Cancer Hospital & Institute. Granta519 tumor cells (1 3 10 7 ) in PBS medium with matrigel (1: 1 ratio) were inoculated subcutaneously into the area under the right flank of each mouse. Treatments were initiated when the tumor volume achieved approximately 100-150 mm 3 . According to the dose of PLS-123 and everolimus used in vivo experiment, 16 ,24 the mice were randomized into four groups (n 5 8/group): vehicle control, everolimus (4 mg/kg) by gavage daily, PLS-123 (20 mg/kg) by intraperitoneal injection daily, and the combination. The tumor tissue samples were collected from the 4 groups at 4 hrs after the lasting dosing. Tumor volume was calculated in according to V 5 ab 2 /2, where a and b denote long and short diameters of the tumor, respectively.
Statistical analysis
All experiments were repeated three times or more and representative results are shown in the figures. Results are expressed as mean 6 SD. Statistical significance from controls was assessed by Student's t test and p < 0.05 values were accepted as statistically significant.
Results
Treatment with low doses of everolimus and PLS-123 has a synergistic effect on MCL cell lines in vitro
To identify drugs that act synergistically in the treatment of MCL, we identified compounds that target various oncogenic pathways in lymphoma and found that co-administration of mTOR inhibitors enhanced anti-tumor activity of BTK inhibitor PLS-123. In the preliminary analysis, we first assessed the anti-tumor effects of everolimus or PLS-123 alone in human MCL cell lines (Supporting Information Fig. 1 ). According to these results, the indicated concentrations of everolimus and PLS-123 were selected for the further combination analysis. Then, the inhibitory activities of this combined treatment on the proliferation of human MCL cell lines (Granta519, Mino, Z138, JVM-2, and Jeko-1) were analyzed using the cell viability assay. The MCL tumor cells were incubated with the fixed concentration of everolimus and increasing concentrations of PLS-123 for 48 hrs. The combination treatment with both reagents resulted in significantly greater inhibitory activity than each agent alone (Fig.  1a) . Furthermore, the combination index (CI) values were used to verify the synergistic anti-tumor effects of everolimus and PLS-123. Significant synergism was observed in combination of these two compounds with CI values < 1 (Fig. 1b) . Time-course analysis of cell proliferation further revealed that prolonged exposure to the two drugs significantly decreased cell proliferation (Fig. 1c) . Meanwhile, the coadministration of PLS-123 and mTOR inhibitor rapamycin also acted synergistically to inhibit cell proliferation (Supporting Information Fig. 2 ).
Co-treatment with low doses of everolimus and PLS-123 synergistically inhibits migration and invasion in MCL
Next the migration and invasion assay were used to evaluate the effects of co-treatment with everolimus and PLS-123 on MCL cell motility. Similar to the previous synergistic inhibitory effect on cell proliferation, the cell migration was attenuated in a dose-dependent manner upon simultaneous exposure of everolimus and PLS-123 (Fig. 2a) . Similarly, co-administration of everolimus and PLS-123 also led to a significant reduction of tumor cells invasion activity (Fig. 2b) . These results suggested that everolimus and PLS-123 act synergistically to reduce cell migration and invasion, and co-treatment with these inhibitors could potentially reduce motility of MCL cells.
Co-administration of everolimus and PLS-123 promotes apoptosis and cell cycle arrest in the G1 phase
To evaluate the cytotoxic effects of co-treatment with everolimus and PLS-123, the apoptotic cells were analyzed following treatment with each drug individually or in combination. In Mino cells, as shown in Figure 3a , treated with everolimus, 16.5 6 2.1% of cells were apoptotic, while 40.7 6 0.9% or 58.5 6 7.6% of cells were apoptotic upon treatment with two different doses of PLS-123. However, co-treatment with varying concentrations of PLS-123 and everolimus led to a significant increase in the percentage of apoptotic cells (79.3 6 7.0% and 94.2 6 2.8%). The similar effect was also observed in Granta519 and Z138 cells, suggesting that everolimus and PLS-123 act synergistically to induce apoptosis in human MCL cells (Fig. 3a) . Furthermore, Western blot analysis revealed that the active forms of Caspase-3 and poly-ADP ribose polymerase (PARP) were significantly increased upon cotreatment, as compared to treatment with either drug alone (Fig. 3b) . These results suggest that the cytotoxicity observed upon treatment with both inhibitors is Caspase-dependent.
Bcl-2 family proteins play a critical role in regulating apoptosis, the expression of these protein were measured by immunoblotting analysis. Simultaneous treatment with everolimus and PLS-123 resulted in marked upregulation of Bax, a pro-apoptotic member of the Bcl-2 family. Meanwhile, the concomitant reduction was observed in several anti-apoptotic Bcl-2 proteins, including Mcl-1, Bcl-xl and X-linked inhibitor of apoptosis protein (XIAP; Fig. 3b ). These findings suggest that co-treatment with everolimus and PLS-123 promotes apoptosis via regulation of mitochondrion-related proteins.
Co-treatment with everolimus and PLS-123 decreased cell proliferation; therefore, we sought to determine whether this attenuation was associated with cell cycle arrest. Next the cell cycle was analyzed post everolimus and PLS-123 co-treatment. Flow cytometry analysis of Mino cells showed that the number of cells in G1 phase significantly increased from 47.11 6 3.62% in the control group to 65.81 6 16.50% and 82.20 6 1.25% in combination treatment group. Meanwhile, the cells number in S phase was sharply reduced post coadministration of everolimus and PLS-123. Similar results were also obtained in Granta519 and Z138 cells (Fig. 3c) . These results indicate that combination treatment with both inhibitors blocked cell cycle progression at the G1 phase. Next the expression of four key proteins (CDK2, CDK4, CDK6 and Cyclin D1) that regulate the G1/S transition were analyzed by immunoblotting analysis. Exposure to both reagents for 48 hrs resulted in significant downregulation of CDK2, CDK4, CDK6 and Cyclin D1, as compared to treatment with each agent alone (Fig. 3d) . These results suggest that co-treatment with everolimus and PLS-123 suppresses proliferation of MCL cells through activation of the apoptotic pathway and induction of cell cycle arrest.
Co-treatment with low doses of everolimus and PLS-123 synergistically downregulates activation of BCR, AKT/ mTOR, JAK2/STAT3 and MAPK signaling in MCL cells
We next investigated the effects of co-treatment with both inhibitors on proteins in related signaling pathways. In Granta519 cells, treatment with PLS-123 alone just slightly reduced phosphorylation of BTK, AKT, JAK2 and ERK1/2, while everolimus alone had little effect on the phosphorylation of these signaling pathways (Fig. 4a) . Co-treatment with everolimus and PLS-123 led to a further reduction in phosphorylation of ERK1/2, BTK, AKT/mTOR, JAK2/STAT3 as compared to each agent alone. The decrease in phosphorylation was most dramatic after 90 min of treatment. Similar results were observed in Mino and Z138 cells (Figs. 4b and  4c ). These data demonstrate that co-administration of everolimus and PLS-123 inhibited transduction of the MAPK, AKT/mTOR and JAK2/STAT3 signaling pathways more effectively than treatment with either drug alone, indicating that these drugs acted synergistically to enhance suppression of these pathways.
Gene expression signatures in MCL are affected by treatment with low doses of everolimus and PLS-123
To gain more comprehensive insight into the biological consequences of BTK and mTOR inhibition in MCL, gene expression profile were measured post combination treatment. As shown in Figure 5a , co-exposure of everolimus and PLS-123 commonly top downregulated representative genes were displayed by a heatmap. Combination treatment could effectively reduce the expression of BCR, mTOR, JAK and MAPK related signaling pathway, which were consistent with results from immunoblotting analysis in Figure 4 .
Moreover, compared with vehicle treatment control, Venn diagram illustrated these inhibitors top down-regulated gene changes (< 21.5 fold, p < 0.05). As shown in Figure 5b , 194 transcripts were significantly reduced after exposure to combination treatment. Approximately 90% of transcripts (19 genes) downregulated by everolimus and 81% of transcripts (59 genes) downregulated by PLS-123 were contained in the combination treatment group. Moreover, 124 transcripts were also efficiently decreased by the combination treatment, which were not present in everolimus or PLS-123 treatment alone. These results demonstrated that combination treatment acted synergistically to regulate gene expression profile.
Next Venn diagram of 124 transcripts changed in combination treatment alone, were then used to select additional anti-tumor mechanisms. The mRNA expression analysis using real-time PCR further indicated that treatment with everolimus and PLS-123 significantly decreased the mRNA levels of SGK1 (Fig. 5c) . As an important downstream effector of PI3K, 25 aberrant SGK1 activity is considered as a significant oncogenic regulator in B-cell lymphoma. [26] [27] [28] The abnormal SGK1 mRNA and protein expression were also confirmed in MCL cell lines (Fig. 5d) .
To investigate the role of SGK1 in MCL cell survival and proliferation, SGK1 knockdown effect on MCL cell viability was examined by shRNA transfection. The reduction of SGK1 expression exhibited anti-proliferative activity towards tumor cells, which indicated SGK1 expression is critical to the survival of MCL cells. Interestingly, the similar proliferation inhibitory effect was observed in SGK1 shRNA and combination treatment, suggesting co-administration of everolimus and PLS-123 might synergistically inhibit MCL cell growth through suppression of SGK1 (Fig. 5e ).
Co-treatment with everolimus and PLS-123 effectively tumor growth in vivo
Given that the everolimus and PLS-123 combination therapy had promising effects on inhibition of MCL cell proliferation in vitro, the anti-tumor activity was analyzed in SCID mice inoculated with Granta519 cells. When the tumor volume was 100-150 mm 3 , the mice were randomized into four treatment groups according to tumor volume and body weight: vehicle control, everolimus (4 mg/kg), PLS-123 (20 mg/kg), and combination of everolimus (4 mg/kg) and PLS-123 (20 mg/kg). Mice were treated with everolimus orally and with PLS-123 intraperitoneally once daily for 15 days. All treatments were well tolerated with no body weight loss, similar to vehicle control animals. Exposure to everolimus or PLS-123 alone resulted in different levels of tumor growth inhibition (70.1 and 47.7%, respectively) in Granta519 xenograft models (Figs. 6a and 6b) . However, in mice treated with the combination of everolimus and PLS-123, tumor growth was inhibited by 84.8%, demonstrating the synergistic activity of these drugs. To further evaluate the apoptosis status of tumor tissue post treatment, TUNEL staining was performed on paraffin sections of tumor samples collected from Granta519 xenografts. As shown in Figure 6c , co-treatment of everolimus and PLS-123 produced a more significant increase of apoptosis compared with each agent alone. Therefore, these results confirmed our in vitro findings, in which everolimus and PLS-123 combination induced MCL cells death via induction of apoptosis.
Discussion
Traditional therapies for MCL have demonstrated limited efficacy, with the majority of patients eventually experiencing relapse. 8 Therefore, there is an urgent need to develop new targeted and combination-based therapeutic regimens for treating this disease. In this study, the combination of mTOR inhibitor everolimus and novel BTK inhibitor PLS-123 acted synergistically to inhibit proliferation of MCL cells through inactivation of related signaling pathways and suppression of SGK1 expression.
The critical role played by the BCR signaling complex in B-cell transformation prompted the development of targeted BTK inhibitors. 9 Ibrutinib, a first-generation BTK inhibitor, presents significant anti-tumor activity in relapsed or refractory MCL patients. 11 However, acquired resistance of ibrutinib induced disease progression is also commonly observed in MCL patients, which highlights the need for the development of new target agents and combination treatment strategies. Subsequently, therapeutic regimens comprising ibrutinib combined with other targeted agents have been developed to treat this disease, such as rituximab, idelalisib, ABT-199 and histone deacetylase inhibitors. [29] [30] [31] [32] [33] A single-centre Phase 2 clinical trial enrolled 50 pretreated relapsed MCL patients who were treated with the combination of ibrutinib and rituximab has demonstrated that this combined therapeutic regime is effective and well tolerated in relapsed or refractory MCL. 29 In chronic lymphocytic leukemia (CLL), several clinical trials of ibrutinib plus rituximab are currently ongoing and revealed that it is also a well-tolerated regimen for patients with high-risk CLL. [34] [35] [36] Our developed novel dualaction BTK inhibitor PLS-123 has also been demonstrated its potential synergistic anti-tumor activity with mTOR inhibitor everolimus in MCL.
The mTOR complex is comprised of two macromolecular complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Activation of mTORC1 induces anabolic cell growth by promoting mRNA translation, protein synthesis, glucose metabolism, and lipid synthesis. Activity of mTORC2 leads to downstream phosphorylation of AKT, SGK1 and PKC, which modulate cell survival and organize the actin cytoskeleton. 37 Although mTOR inhibitor rapamycin and its analog everolimus primarily target mTORC1, the drug efficacy is limited by feedback activation of PI3K signaling and AKT rephosphorylation. 38, 39 This feedback mechanism may explain the possible reason of everolimus resistance, which highlighted the combination treatment targeting the PI3K/AKT/mTOR pathway to prevent AKT reactivation. Current evidence has revealed that the BCR promotes the activating of downstream signaling, including NF-jB, PI3K, MAPK and NFAT pathways. 10 Inactivation of BCR signaling by targeting BTK inhibitor could significantly attenuate the activation of PI3K signaling. Therefore, the combination of PLS-123 and everolimus may induce synergic anti-tumor activity through suppression of PI3K signaling pathway reactivation. Furthermore, co-treatment with everolimus and PLS-123 also significantly suppressed the activity of the JAK2/STAT3 signaling pathway, suggesting an indirect synergistic mechanism of action. Similarly, Ezell et al.also demonstrated that that co-treatment of diffuse large B-cell lymphoma (DLBCL) with the mTOR inhibitor AZD2014 and the BTK inhibitor ibrutinib significantly reduced phosphorylation of STAT3 through inhibition of NFjB/IL-10 autocrine loop. 40 Moreover, STAT3 signaling is positively regulated by PI3K/mTOR signaling, 41 suggesting a mechanism by which the combination treatment of everolimus and PLS-123 could synergistically inhibit activation of JAK2/ STAT3 signaling. The serine/threonine protein kinase SGK1 shares structural and functional similarities with the AKT family of kinases. The activation of SGK1 is regulated through mTORdependent phosphorylation and can be further activated by 3-phosphoinositide-dependent kinase-1. 42 Previous studies have demonstrated that suppression of SGK1 activity, either by silencing or through use of specific inhibitors, results in apoptosis and cell cycle arrest in several cancer cell lines, suggesting the essential role of SGK1 in survival and proliferation of malignant tumor cells. 27, 28, 43 Our results reveal that treatment of MCL with a combination of everolimus and PLS-123 significantly reduced gene expression of SGK1. The shRNAmediated reduction in SGK1 expression significantly reduces MCL cell proliferation. This notion indicated that reduction in SGK1 could be an important biological mechanism by which inhibitors of BTK and mTOR act synergistically to suppress cell growth. However, further experimentations are still needed to explore the precise mechanism in detail. Our study supports a rational basis for co-administration of inhibitors of BTK and mTOR for the treatment of MCL. The mechanistic studies provide an explanation for the synergistic effect of these two compounds, which were also validated using in vivo assays. Taken together, these results demonstrate that the simultaneous suppression of BTK and mTOR may be a promising therapeutic regimen for MCL.
